Edge-to-Edge Repair in Atrial Secondary Tricuspid Regurgitation

Tricuspid regurgitation (TR) has been associated with higher morbimortality and a negative impact on quality of life. 

La insuficiencia renal post tratamiento borde a borde tricuspídeo impacta en el pronóstico

In most cases, its main cause is a condition of the left heart. However, in lower proportion, it may also be due to significant right atrium dilation compared against the right ventricle (Atrial Secondary Tricuspid Regurgitation, A-SRT). The latter has not been studied enough and little is known about its prognosis. 

Tricuspid edge-to-edge repair (T-TEER) has been shown safe and effective, improving quality of life and reducing hospitalization for cardiac failure. However, its efficacy in the context of A-SRT has not been thoroughly assessed.

This was a EuroTR Registry analysis including 641 patients with moderate to severe TR receiving T-TEER. 196 (30,5 %) of these patients presented A-SRT, while the rest had non-atrial secondary TR (N-SRT).

Read also: PULSE Registry Subanalysis: Radial vs. Femoral Secondary Access.

MitraClip, TriClip and PASCAL were used.

Mean patient age was 79. A-SRT patients showed higher prevalence of atrial fibrillation, less comorbidities and better biventricular function. Most were in functional class III-IV.

TR severity was 3+ in 47% of cases, 4+ in 41%, and 5+ in 18%.

After procedure, even though both groups saw TR reduction, the proportion of TR ≤ 2 was lower among A-SRT patients (86,9 % vs. 80,4 %; p=0,005).

Read also: Percutaneous Treatment of Tricuspid Regurgitation with K-CLIP.

At two-year follow-up, survival was significantly higher among A-SRT patients (66,7 % vs. 44,3 %; p<0,001), as was CF hospitalization reduction (66,3 % vs. 47,5 %; p<0,001). Both groups experienced improved functional class, but the proportion of patients with CF in functional class ≥ III was lower among A-SRT patients (38 % vs. 46 %; p=0,033). 

Conclusion

A-SRT is a common STR phenotype associated to effective reduction of TR and improved symptoms after T TEER. 

Original Title: Atrial Secondary Tricuspid Regurgitation Insights Into the EuroTR Registry.

Reference: Lukas Stolz, et al. JACC Cardiovasc Interv. 2024;17:2781–2791.


Subscribe to our weekly newsletter

Get the latest scientific articles on interventional cardiology

Dr. Carlos Fava
Dr. Carlos Fava
Member of the Editorial Board of solaci.org

More articles by this author

Measuring Post-TAVI Gradients and Their Implications: Are Invasive and Echocardiographic Assessments Comparable?

Transcatheter aortic valve implantation (TAVI) is considered the treatment of choice for a significant proportion of patients with symptomatic aortic stenosis. Outcomes have improved...

Percutaneous Tricuspid Valve Replacement with Lux-Valve

Tricuspid regurgitation (TR) is a condition associated with poor quality of life, frequent hospitalizations due to heart failure, and increased mortality, even under optimal...

TAVR in Small Annuli: What Valve Should We Use?

One of the major challenges of severe aortic stenosis are patients with small aortic annuli, defined as ≤430 mm² aortic valve area. This condition...

ACC 2025 | TAVI in Low-Risk Patients: 5-Year Outcomes of EVOLUTE LOW RISK

Transcatheter aortic valve implantation (TAVI) is a valid alternative to surgery in low-risk patients with severe aortic stenosis. However, one of its main limitations...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

Pretreatment with DAPT in Acute Coronary Syndrome: An Ongoing Debate?

In acute coronary syndrome (ACS) dual antiplatelet therapy (DAPT) has become a fundamental pillar after percutaneous coronary intervention (PCI), preventing stent thrombosis and acute...

Measuring Post-TAVI Gradients and Their Implications: Are Invasive and Echocardiographic Assessments Comparable?

Transcatheter aortic valve implantation (TAVI) is considered the treatment of choice for a significant proportion of patients with symptomatic aortic stenosis. Outcomes have improved...

Another Blow for Intra-Aortic Balloon Pumo Counterpulsation? Randomized Study on Its Use in Chronic Heart Failure Progressing to Cardiogenic Shock

Cardiogenic shock (CS) remains a condition with extremely high mortality (around 50%). While most therapies for this pathology have been studied in CS secondary...